Publication date: Available online 9 February 2018
Source:Bioorganic & Medicinal Chemistry
Author(s): Ryo Eto, Takashi Misawa, Tomomi Noguchi-Yachide, Nobumichi Ohoka, Masaaki Kurihara, Mikihiko Naito, Masakazu Tanaka, Yosuke Demizu
The estrogen receptor (ER), a member of the nuclear receptor (NR) family, is involved in the regulation of physiological effects such as reproduction and bone homeostasis. Approximately 70% of human breast cancers are hormone-dependent and ERα-positive, and, thus, ER antagonists are broadly used in breast cancer therapy. We herein designed and synthesized a set of ER antagonists with a 4-heterocycle-4-phenylheptane skeleton.
Graphical abstract
http://ift.tt/2EwjVmt
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου